MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ygyno.2022.10.020

Медицинская библиотека · Gynecologic oncology · 2022

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.

Ackroyd Sarah A, Arguello David, Ramos Pilar, Mahdi Haider, ElNaggar Adam, Winer Ira, Holloway Rob, Krivak Thomas, Jones Nathaniel, Turner Valerie Galvan, Herzog Thomas, Chu Christina, Brown Jubilee, Mantia-Smaldone Gina

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Advanced clear cell gynecologic malignancies remain among the most challenging diseases to manage. We evaluated ovarian and endometrial clear cell carcinoma (OCCC and ECCC) specimens using comprehensive sequencing technology to identify mutational targets and compared their molecular profiles to histologically similar clear cell renal cell carcinoma (ccRCC).

METHODS

Using next-generation sequencing (NGS), fragment analysis (FA), and in situ hybridization (ISH), 164 OCCC, 75 ECCC and 234 ccRCC specimens from 2015 to 2018 were evaluated and compared.

RESULTS

The highest mutation rates in ECCC and OCCC were noted in: ARID1A (75.0%, 87.5%), TP53 (34.8%, 11.1%), PIK3CA (25.0%, 46.8%), PPP2R1A (8.7%, 16.7%), MSI-high (8.8%, 6.4%) and PTEN (8.3%, 7.1%). Among these mutations, there was no significant difference between OCCC and ECCC mutation prevalence except in TP53, with higher mutation rates in ECCC versus OCCC (34.8 vs. 11.1%, respectively, p < 0.05). ccRCC demonstrated different mutation profiles with higher mutation rates in VHL (80.3%), PBRM1 (43.9%), SETD2 (31.1%), and KDM5C (29.2%). By contrast, VHL, PBRM1, and SETD2 mutations were not found in ECCC and OCCC (0.0%). Compared to ccRCC and ECCC, OCCC was found to have a significantly higher tumor mutation burden (TMB) (19.1%).

CONCLUSION

Gynecologic and renal CCC demonstrate separate and disparate somatic profiles. However, OCCC and ECCC are diseases with similar profiles. TMB and MSI analyses indicate that a subset of OCCC may benefit from immunotherapy. Prospective clinical trials are needed and are underway to examine targeted therapies in these gynecologic disease subtypes.

Для цитирования: Ackroyd Sarah A, Arguello David, Ramos Pilar, Mahdi Haider, ElNaggar Adam, Winer Ira, Holloway Rob, Krivak Thomas, Jones Nathaniel, Turner Valerie Galvan, Herzog Thomas, Chu Christina, Brown Jubilee, Mantia-Smaldone Gina. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.. Gynecologic oncology. 2022. DOI: 10.1016/j.ygyno.2022.10.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.